Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia

[1]  G. Eschweiler,et al.  Multicenter Study. , 2019, Deutsches Arzteblatt international.

[2]  W. Vainchenker,et al.  Faculty of 1000 evaluation for Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. , 2018 .

[3]  K. Rau,et al.  A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy , 2016, Medicine.

[4]  J. Nemunaitis,et al.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Hirakawa,et al.  Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. , 2015, Anticancer research.

[6]  T. Sendo,et al.  Refractory cachexia is associated with increased plasma concentrations of fentanyl in cancer patients , 2015, Therapeutics and clinical risk management.

[7]  S. Hughes,et al.  The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people , 2015, British Journal of Cancer.

[8]  P. Ravasco,et al.  Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. , 2015, Nutrition.

[9]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[10]  J. W. Kim,et al.  Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.

[11]  S. Anker,et al.  Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014 , 2014, Journal of cachexia, sarcopenia and muscle.

[12]  Julien Taieb,et al.  Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer , 2014, Nutrition and cancer.

[13]  Yasuhiro Inoue,et al.  Correlation between preoperative systemic inflammation and postoperative infection in patients with gastrointestinal cancer: a multicenter study , 2014, Surgery Today.

[14]  Y. Toiyama,et al.  Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment , 2013, Oncology letters.

[15]  S. Lydersen,et al.  Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. , 2013, Clinical nutrition.

[16]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[17]  J. Giesy,et al.  Protective effects of eicosapentaenoic acid on genotoxicity and oxidative stress of cyclophosphamide in mice , 2011, Environmental toxicology.

[18]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[19]  T. Reiman,et al.  Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy , 2011, Cancer.

[20]  T. Ziegler,et al.  Nutritional interventions for cancer-induced cachexia. , 2011, Current problems in cancer.

[21]  奥川 喜永.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer , 2011 .

[22]  Y. Toiyama,et al.  Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. , 2011, Experimental and therapeutic medicine.

[23]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[24]  A. Gasbarrini,et al.  Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin / þ Mice , 2010 .

[25]  Y. Toiyama,et al.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer , 2010, British Journal of Cancer.

[26]  T. Reiman,et al.  Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. , 2010, The Journal of nutrition.

[27]  L. Mccargar,et al.  Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment , 2009, Clinical Cancer Research.

[28]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[29]  D. McMillan,et al.  An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer , 2008, Proceedings of the Nutrition Society.

[30]  P. Calder.  Immunomodulation by omega-3 fatty acids. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[31]  G. Murray,et al.  Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Fearon,et al.  Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. , 2006, The American journal of clinical nutrition.

[33]  D. Jho,et al.  Role of Omega-3 Fatty Acid Supplementation in Inflammation and Malignancy , 2004, Integrative cancer therapies.

[34]  N. Aaronson,et al.  Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.

[35]  H. Tonouchi,et al.  Intra‐tumoral interleukin‐6 down‐regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma , 2002, Cancer.

[36]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[37]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[38]  The International Consensus , 1992, The Rights of the Child and the Changing Image of Childhood.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.